{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:26:51Z","timestamp":1772936811162,"version":"3.50.1"},"reference-count":131,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Jiangsu Funding Program for Excellent Postdoctoral Talent","award":["2022ZB894"],"award-info":[{"award-number":["2022ZB894"]}]},{"name":"Social and Livelihood Science and Technology Project of Nantong","award":["MSZ2023057"],"award-info":[{"award-number":["MSZ2023057"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR-T) cell therapy has been widely used in haematological malignancies and has achieved remarkable results. However, two major toxicities of CAR-T-cell therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, have been reported in many studies and often require hospitalization. There is evidence that CAR-T-cell therapy is being increasingly used clinically, so it is important to pay attention to its serious adverse events that may be life-threatening. In this review, we provide a detailed discussion of the clinical manifestations, classification, risk factors, and management and treatment of serious adverse events to provide theoretical support for clinicians to manage such cases. Although the clinical application of CAR-T cells continues to expand, adverse events associated with CAR-T-cell therapy are inevitable. With the identification of risk factors and the application of various new therapeutic approaches, the incidence and severity of these adverse events can be effectively controlled.<\/jats:p>","DOI":"10.1093\/carcin\/bgaf083","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:46:24Z","timestamp":1766321184000},"source":"Crossref","is-referenced-by-count":0,"title":["Adverse events and recent advances in CAR-T-cell therapy"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-9679","authenticated-orcid":false,"given":"Zhimin","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Chongchuan District, Nantong, Jiangsu 226001 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical School, Nantong University, 9 Seyuan Road, Nantong, Jiangsu 226019 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Chongchuan District, Nantong, Jiangsu 226001 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5782-4620","authenticated-orcid":false,"given":"Zenghua","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Chongchuan District, Nantong, Jiangsu 226001 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4495","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Nantong University, No. 20 Xisi Road, Chongchuan District, Nantong, Jiangsu 226001 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"2026030703170252100_bgaf083-B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2026030703170252100_bgaf083-B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"2026030703170252100_bgaf083-B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026030703170252100_bgaf083-B4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026030703170252100_bgaf083-B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026030703170252100_bgaf083-B6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"2026030703170252100_bgaf083-B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-020-00890-6","article-title":"Gene modification strategies for next-generation CAR T cells against solid cancers","volume":"13","author":"Tian","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B9","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"2026030703170252100_bgaf083-B10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026030703170252100_bgaf083-B11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B12","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B13","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"2026030703170252100_bgaf083-B15","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"2026030703170252100_bgaf083-B16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"key":"2026030703170252100_bgaf083-B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"key":"2026030703170252100_bgaf083-B18","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.cell.2020.07.018","article-title":"Multiple signaling roles of CD3epsilon and its application in CAR-T cell therapy","volume":"182","author":"Wu","year":"2020","journal-title":"Cell"},{"key":"2026030703170252100_bgaf083-B19","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","article-title":"Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing","volume":"15","author":"Jacob","year":"2020","journal-title":"Nat Protoc"},{"key":"2026030703170252100_bgaf083-B20","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.7150\/ijbs.70120","article-title":"CAR-T Cell therapy for breast cancer: from basic research to clinical application","volume":"18","author":"Yang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2026030703170252100_bgaf083-B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"2026030703170252100_bgaf083-B22","doi-asserted-by":"publisher","first-page":"2702882","DOI":"10.1155\/2023\/2702882","article-title":"Effects of CAR-T cell therapy on immune cells and related toxic Side effect analysis in patients with refractory acute lymphoblastic leukemia","volume":"2023","author":"Li","year":"2023","journal-title":"Mediators Inflamm"},{"key":"2026030703170252100_bgaf083-B23","doi-asserted-by":"publisher","first-page":"1171031","DOI":"10.3389\/fonc.2023.1171031","article-title":"Case report: severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS","volume":"13","author":"Masucci","year":"2023","journal-title":"Front Oncol"},{"key":"2026030703170252100_bgaf083-B24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"key":"2026030703170252100_bgaf083-B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"2026030703170252100_bgaf083-B26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B27","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"2026030703170252100_bgaf083-B29","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; A review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party (ADWP) and transplant complications working party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front Immunol"},{"key":"2026030703170252100_bgaf083-B31","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/10428194.2021.2024817","article-title":"Low utility of the H-score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026030703170252100_bgaf083-B32","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026030703170252100_bgaf083-B33","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1136\/ard-2023-224123","article-title":"The 2022 EULAR\/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS)","volume":"82","author":"Shakoory","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026030703170252100_bgaf083-B34","doi-asserted-by":"publisher","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Martin-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"2026030703170252100_bgaf083-B35","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B37","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026030703170252100_bgaf083-B38","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026030703170252100_bgaf083-B40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"2026030703170252100_bgaf083-B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026030703170252100_bgaf083-B42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2026030703170252100_bgaf083-B43","doi-asserted-by":"publisher","first-page":"807050","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"key":"2026030703170252100_bgaf083-B44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"2026030703170252100_bgaf083-B45","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B46","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jamainternmed.2021.4826","article-title":"Comparison of classification of indications for allogeneic and autologous transplant for adults in ASTCT guidelines and evidence available in published literature","volume":"182","author":"Kim","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2026030703170252100_bgaf083-B47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026030703170252100_bgaf083-B48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026030703170252100_bgaf083-B49","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"2026030703170252100_bgaf083-B50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41408-022-00657-x","article-title":"Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)","volume":"12","author":"Saw","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026030703170252100_bgaf083-B51","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B52","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv"},{"key":"2026030703170252100_bgaf083-B53","doi-asserted-by":"publisher","first-page":"1058126","DOI":"10.3389\/fimmu.2022.1058126","article-title":"Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity","volume":"13","author":"De Matteis","year":"2022","journal-title":"Front Immunol"},{"key":"2026030703170252100_bgaf083-B54","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2019-03-900985","article-title":"CAR-T-cell neurotoxicity: hope is on the horizon","volume":"133","author":"Ahmed","year":"2019","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B55","doi-asserted-by":"publisher","first-page":"994885","DOI":"10.3389\/fimmu.2022.994885","article-title":"Transcriptional states of CAR-T infusion relate to neurotoxicity\u2014lessons from high-resolution single-cell SOM expression portraying","volume":"13","author":"Loeffler-Wirth","year":"2022","journal-title":"Front Immunol"},{"key":"2026030703170252100_bgaf083-B56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/bjh.19015","article-title":"Severe persistent neurotoxicity associated with CAR T therapy in children","volume":"203","author":"Andrew","year":"2023","journal-title":"Br J Haematol"},{"key":"2026030703170252100_bgaf083-B57","doi-asserted-by":"publisher","first-page":"1206983","DOI":"10.3389\/fonc.2023.1206983","article-title":"CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap","volume":"13","author":"Gatto","year":"2023","journal-title":"Front Oncol"},{"key":"2026030703170252100_bgaf083-B58","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"2026030703170252100_bgaf083-B59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11307-021-01672-3","article-title":"Visualizing CAR-T cell immunotherapy using 3 tesla fluorine-19 MRI","volume":"24","author":"Dubois","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"2026030703170252100_bgaf083-B60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","article-title":"Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT","volume":"15","author":"Breen","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B61","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41408-023-00895-7","article-title":"Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to axicabtagene ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity","volume":"13","author":"Breen","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026030703170252100_bgaf083-B62","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B63","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B64","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"key":"2026030703170252100_bgaf083-B65","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1038\/s41409-021-01471-y","article-title":"Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement","volume":"56","author":"Hu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B66","doi-asserted-by":"publisher","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","article-title":"Therapeutic potential of TNFalpha and IL1beta blockade for CRS\/ICANS in CAR-T therapy via ameliorating endothelial activation","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2026030703170252100_bgaf083-B67","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B68","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11910-023-01315-w","article-title":"Neurotoxicity of cancer immunotherapies including CAR T cell therapy","volume":"23","author":"Song","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026030703170252100_bgaf083-B69","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00277-023-05507-9","article-title":"Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy","volume":"103","author":"Winkelmann","year":"2024","journal-title":"Ann Hematol"},{"key":"2026030703170252100_bgaf083-B71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnen\/nlac121","article-title":"Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma","volume":"82","author":"Nie","year":"2023","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026030703170252100_bgaf083-B72","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.bulcan.2021.10.004","article-title":"Complications other than infections, CRS and ICANS following CAR T-cells therapy: recommendations of the francophone society of bone marrow transplantation and cell therapy (SFGM-TC)","volume":"108","author":"Pochon","year":"2021","journal-title":"Bull Cancer"},{"key":"2026030703170252100_bgaf083-B73","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/19418744221128852","article-title":"Continuous EEG monitoring detects nonconvulsive seizure and ictal-interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy","volume":"13","author":"Satyanarayan","year":"2023","journal-title":"Neurohospitalist"},{"key":"2026030703170252100_bgaf083-B74","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s00259-021-05562-2","article-title":"2-[18F]FDG-PET\/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS","volume":"49","author":"Paccagnella","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026030703170252100_bgaf083-B75","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"key":"2026030703170252100_bgaf083-B76","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov"},{"key":"2026030703170252100_bgaf083-B77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"key":"2026030703170252100_bgaf083-B78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026030703170252100_bgaf083-B79","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2026030703170252100_bgaf083-B80","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B81","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B82","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B83","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-021-01101-6","article-title":"CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients","volume":"14","author":"Ke","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B85","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s40425-019-0804-9","article-title":"Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity","volume":"7","author":"Torres Chavez","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026030703170252100_bgaf083-B86","doi-asserted-by":"publisher","first-page":"702152","DOI":"10.3389\/fphar.2021.702152","article-title":"Cytokine release syndrome is an independent risk factor associated with platelet transfusion refractoriness after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026030703170252100_bgaf083-B87","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/neuonc\/noab174","article-title":"EEG findings in CAR T-cell-associated neurotoxicity: clinical and radiological correlations","volume":"24","author":"Beuchat","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026030703170252100_bgaf083-B88","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41563-023-01646-6","article-title":"In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity","volume":"22","author":"Gong","year":"2023","journal-title":"Nat Mater"},{"key":"2026030703170252100_bgaf083-B89","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","article-title":"CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: is it still a concern?","volume":"14","author":"Velasco","year":"2023","journal-title":"Front Neurol"},{"key":"2026030703170252100_bgaf083-B90","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","article-title":"Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia","volume":"13","author":"Gu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B91","doi-asserted-by":"publisher","first-page":"107411","DOI":"10.1016\/j.biotechadv.2019.06.010","article-title":"CAR-T immunotherapies: biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering","volume":"37","author":"Panagopoulou","year":"2019","journal-title":"Biotechnol Adv"},{"key":"2026030703170252100_bgaf083-B92","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026030703170252100_bgaf083-B93","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"2026030703170252100_bgaf083-B94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026030703170252100_bgaf083-B95","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv"},{"key":"2026030703170252100_bgaf083-B96","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026030703170252100_bgaf083-B97","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030703170252100_bgaf083-B98","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2026030703170252100_bgaf083-B99","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2026030703170252100_bgaf083-B100","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B101","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026030703170252100_bgaf083-B102","doi-asserted-by":"publisher","first-page":"215920","DOI":"10.1016\/j.canlet.2022.215920","article-title":"Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective","volume":"550","author":"Si","year":"2022","journal-title":"Cancer Lett"},{"key":"2026030703170252100_bgaf083-B103","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-A brief review of a Complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026030703170252100_bgaf083-B104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026030703170252100_bgaf083-B105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2022016855","article-title":"Buckling up against COVID-19 after CAR T-cell therapy","volume":"140","author":"Auletta","year":"2022","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B106","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv"},{"key":"2026030703170252100_bgaf083-B107","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1470-2045(21)00695-1","article-title":"Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era","volume":"23","author":"Abid","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026030703170252100_bgaf083-B108","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol Ther"},{"key":"2026030703170252100_bgaf083-B109","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv"},{"key":"2026030703170252100_bgaf083-B110","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030703170252100_bgaf083-B111","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B112","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030703170252100_bgaf083-B113","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2026030703170252100_bgaf083-B114","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/ejh.14052","article-title":"Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): a comprehensive review on incidence, risk factors and current management","volume":"112","author":"Galli","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026030703170252100_bgaf083-B115","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","article-title":"Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"12","author":"Acharya","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"2026030703170252100_bgaf083-B116"},{"key":"2026030703170252100_bgaf083-B117","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"2026030703170252100_bgaf083-B118","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14656566.2024.2340738","article-title":"Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy","volume":"25","author":"Walton","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026030703170252100_bgaf083-B119","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2016.262","article-title":"Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms","volume":"31","author":"Ruella","year":"2017","journal-title":"Leukemia"},{"key":"2026030703170252100_bgaf083-B120","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B121","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026030703170252100_bgaf083-B122","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1126\/science.373.6553.372","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"373","author":"Weber","year":"2021","journal-title":"Science"},{"key":"2026030703170252100_bgaf083-B123","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"2026030703170252100_bgaf083-B124","doi-asserted-by":"publisher","first-page":"e25786","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report","volume":"100","author":"Zi","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026030703170252100_bgaf083-B125","doi-asserted-by":"publisher","first-page":"438 e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026030703170252100_bgaf083-B126","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2147\/IJN.S445101","article-title":"Emerging strategies to overcome current CAR-T therapy dilemmas\u2014exosomes derived from CAR-T cells","volume":"19","author":"Hu","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"2026030703170252100_bgaf083-B127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunother"},{"key":"2026030703170252100_bgaf083-B128","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3Kdelta\/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B129","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","article-title":"Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"2026030703170252100_bgaf083-B130","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"2026030703170252100_bgaf083-B131","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","article-title":"CAR-T cell combination therapies in hematologic malignancies","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp Hematol Oncol"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgaf083\/66130816\/bgaf083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/47\/1\/bgaf083\/66130816\/bgaf083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/carcin\/article-pdf\/47\/1\/bgaf083\/66130816\/bgaf083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:17:07Z","timestamp":1772871427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/doi\/10.1093\/carcin\/bgaf083\/8405148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgaf083","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"bgaf083"}}